Collaborative arrangement profit share percentage.

No definition available.

Name:	adro_CollaborativeArrangementProfitSharePercentage
Namespace Prefix:	adro_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Period after first sale of product.

+ References

No definition available.

+ Details

Name:	adro_PeriodAfterFirstSaleOfProduct
Namespace Prefix:	adro_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Reduction percentage of development cost share.

+ References

No definition available.

+ Details

Name:	adro_ReductionPercentageOfDevelopmentCostShare
Namespace Prefix:	adro_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Reduction percentage of profit share.

+ References

No definition available.

+ Details

Name:	adro_ReductionPercentageOfProfitShare
Namespace Prefix:	adro_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue recognition milestone method eligible revenue development milestones.

+ References

No definition available.

+ Details

Name:	adro_RevenueRecognitionMilestoneMethodEligibleRevenueDevelopmentMilestones
Namespace Prefix:	adro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue recognition milestone method eligible revenue for each product or product candidate.

+ References

No definition available.

+ Details

Name:	adro_RevenueRecognitionMilestoneMethodEligibleRevenueForEachProductOrProductCandidate
Namespace Prefix:	adro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue recognition milestone method eligible revenue regulatory approval milestones.

+ References

No definition available.

+ Details

Name:	adro_RevenueRecognitionMilestoneMethodEligibleRevenueRegulatoryApprovalMilestones
Namespace Prefix:	adro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Novartis share of joint development costs.

+ References

No definition available.

+ Details

Name:	adro_ShareOfJointDevelopmentCosts
Namespace Prefix:	adro_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Transaction price allocated to combined performance obligation.

+ References

No definition available.

+ Details

Name:	adro_TransactionPriceAllocatedToCombinedPerformanceObligation
Namespace Prefix:	adro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Description of rights and obligations under the collaborative arrangements.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_CollaborativeArrangementRightsAndObligations
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130554-203045

+ Details

Name:	us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=adro_NovartisAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=adro_SpecifiedEuropeanCountriesAndJapanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=adro_UnitedStatesSpecifiedEuropeanCountriesAndOrJapanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=adro_NovartisPharmaceuticalsCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=adro_LillyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=adro_MerckLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=adro_ProductCandidateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended			12 Months Ended	48 Months Ended
	Apr. 30, 2015	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2016	Dec. 31, 2017	Mar. 31, 2019
Novartis Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received under collaboration agreement	$ 200,000,000			$ 35,000,000		$ 1,600,000
Novartis share of joint development costs		38.00%
Period after first commercial sale of product on which Novartis' royalty obligation run on a country to country basis		12 years
Transaction price allocated to combined performance obligation		$ 236,600,000
Revenue recognized		2,500,000	$ 3,600,000
Deferred revenue		$ 174,100,000				174,100,000
Novartis Agreement \| United States
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement profit share percentage		50.00%
Novartis Agreement \| European Countries and Japan
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement profit share percentage		45.00%
Novartis Agreement \| United States, Specified European Countries and /or Japan
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative Agreement, Obligations		With respect to the United States, specified European countries and/or Japan, the Company may elect for such region to either reduce by 50% or to eliminate in full the Company’s development and commercialization cost sharing obligation. If the Company elects to reduce its cost sharing percentage by 50% in any such region, then its profit share in such region will also be reduced by 50%. If the Company elects to eliminate its development cost sharing obligation, then such region will be removed from the profit share, and instead Novartis will owe the Company royalties on any net sales of product for such region, as described above.
Reduction percentage of development cost share		50.00%
Reduction percentage of profit share		50.00%
Novartis Agreement \| Novartis
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Novartis share of joint development costs		62.00%
Collaborative arrangement profit share percentage		50.00%
Novartis Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestones amount eligible to receive		$ 215,000,000
Regulatory approval milestones amount eligible to receive		250,000,000
Lilly Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received under collaboration agreement		12,000,000
Revenue recognized		1,400,000
Deferred revenue		$ 11,400,000				$ 11,400,000
Royalty payments receivable terms		Lilly is also obligated to pay the Company tiered royalty payments at percentages in the single to low-double digits based on annual net sales of the licensed products. Lilly must pay such royalties on a product-by-product and country-by-country basis until the latest to occur of (i) the expiration of the last-to-expire valid claim of certain patents, (ii) the expiration of the data exclusivity period in such country or (iii) a specified anniversary of the first commercial sale of such product in such country.
Lilly Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates		$ 620,000,000
Merck License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received under collaboration agreement			3,000,000		$ 2,000,000
Remaining performance obligations			$ 0		$ 0
Merck License Agreement \| Maximum \| Product Candidate
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates		307,000,000
Merck License Agreement \| Maximum \| Product
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates		$ 135,000,000